Eric Lefkofsky Developing Clinical Library for Better Treatment

Eric Lefkofsky has been known in the business world for the tremendous success he has achieved over the years with numerous start-ups and businesses. He is also popular for being the co-founder of Groupon, a start-up that went on to become a billion dollar enterprise. Eric Lefkofsky is currently focused on his new start-up by the name of Tempus, which is a company that’s focused on gathering the molecular and clinical data of the patients. Eric Lefkofsky says that with the help of data provided by Tempus, the physicians across the globe would be able to make sound and more effective treatment decisions.

Recently, Eric Lefkofsky announced the completion of series E funding for Tempus of $110 million. The company also announced that it had launched the mobile app of its services that would allow the physicians to access the molecular and clinical data of the patients on their phone itself. The good thing about Tempus’s new mobile app is that now the physicians do not have to take out time from their busy schedule to sit on their computers to access the data, but can do so directly from their phone while on the move. The team at Tempus did extensive research as well as incorporated feedback from the physicians before developing Tempus Labs mobile app.

Currently, the physicians across the globe don’t have the easy access to clinical data that they would require to make better treatment decisions for the patients. The COO of Tempus Labs believes that it is necessary for physicians to get access to such clinical data to make smart treatment decisions. With the recent funding round, Tempus is planning to expand its operations globally. The operating system developed by Tempus is continually adding clinical and molecular information from different medical facilities. Ensuring that the physicians have sufficient information necessary to make smart treatment decisions are the ultimate aim of Tempus. With time to come, many new diseases and illnesses would be covered by the Tempus to allow physicians to be able to treat patients with different medical issues get better treatment. Tempus is bringing in a revolution in the medical field with its clinical library.

CLAY SIEGALL ACCOMPLISHMENT.

Seattle Genetics was founded in 1998 and deals with manipulating, studying and packaging of drugs. The company has a market value of approximately $10 billion and employees of roughly 900. The company is ranked as the largest in Washington in the biotechnology field. The company has substantial investments in the marketing and research with the aim of employing 200 more staff as a path towards becoming a pharmaceutical company.

The company previously launched adcetrics, a drug that treats Hodgkin lymphoma, a lymph system cancer that quickly spreads to other body systems once in the body of a human being. The drug has been undergoing several tests, and with positive feedback, the sale of the drug will take off. Clay Siegall, the Chief Executive Officer, President, chairman of the executive and co-founder of the company explains the many drugs in their pipeline as confirmation of their desire to become a pharmaceutical industry. In raising capital for the company to research on the adcetrics, they sold their international rights and partnered with Takeda Oncology. With their partnership with the Takeda Oncology, Seattle Genetics learned several techniques used in global markets, and recently they opened an international marketing office in Switzerland that will enhance their global markets.

The company is on a steep escalation in the global markets. In the year 2016, the company made sales of close to 28 million dollars, a 46% rise from the year 2014. The company’s stock price has tripled in the past five years from one share rising from $20 to $66. Several analysts bet on the prospect takeover based on the firm’s increasing valuation

Prior to co-founding Seattle Genetics, Clay Siegall worked for Bristol-Myers Squibb Research Institute in the year 1988-1991, National Health Institute from 1988-1991 and the National Cancer Institute. He is a board member of the Alder Biopharmaceuticals, a company that is privately owned and specializes in biotechnology and a private biotechnology company, Mirna Therapeutic. He is also an author of over 70 publications, and he also owns 15 patents.

Clay Siegall received his bachelor’s degree in zoology from the Maryland University, and he also owns a Ph.D. in Genetics from the University of George Washington.

In 2014, Ultragenyx Pharmaceuticals appointed Clay Siegall as one of the executive committees. Ultragenyx Pharmaceutical Incorporation is a biopharmaceutical company that focuses on the advancement of novel products for ultra-rare and rare disease.